TELA Bio Inc (NASDAQ:TELA), a producer of soft tissue reconstruction implants, raised $52 million in its IPO after offering 4 million shares at $13 each, which was below its projected range of $14 to $16.
The company, based in Malvern, Pennsylvania, offers reinforcing implants used in hernia repair, abdominal wall reconstruction, as well as plastic and reconstructive surgery. Its products have been used in more than 6,500 patients, the company said.
Shares opened at $13.91 and rose to $15, more than 15% above its IPO price.
ECMOHO Ltd (NASDAQ:MOHO), an online health and wellness retailer based in Shanghai, raised $44 million by offering 4.4 million shares at $10 per share, the low end of its $10 to $12 range.
The seven-year-old company bills itself as a provider of personalized health supplements, food, personal care products, household healthcare equipment and more. ECMOHO was China’s top non-medical health and wellness integrated solution industry in terms of revenue in 2018 with a market share of 2.6%, according to Frost & Sullivan.
ECMOHO stock debuted at $10.10 and slid to $9.99, 0.1% below its IPO price.
36KR Holdings Inc (NASDAQ:KRKR), a Chinese online media publisher, completed a $20 million downsized IPO.
The company offered 1.4 million shares — 2.2 million fewer than originally planned — at $14.50 per share, the low end of its $14.50 to $17.50 range.
The Beijing-based company bills itself a top coverage provider of so-called new economy content and has expanded to provide business offerings such as online advertising services, enterprise value-added services and subscription services.
The company claims to be the first to cover ByteDance, the Chinese company behind TikTok, back in January 2013.
36KR opened trading at $12.58 and dipped to $13.90, 4.1% lower than its IPO price.
CNS Pharmaceuticals Inc (NASDAQ:CNSP), a Houston biotechnology company focused on brain cancer therapies, raised $9 million after offering 2.1 million shares and pricing at the low end of its estimated $4 to $5 range.
The company, originally scheduled to go public last week, is developing drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its lead drug candidate, Berubicin, is designed to treat glioblastoma, a type of brain cancer currently considered to be incurable.
Shares started trading at $4.11 and climbed to $4.40, 10% above its IPO price.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel